Anavex Life Sciences Corp (AVXL)

[Investor2014]

OFP,

Not that it matters, but I did not have to pay $40 for access to the full paper.

You may have noticed that the paper is broadly spilt into two sections discussing the compounds in physiological (normal) and pathological (disease) conditions.

In short I do believe the ineffectiveness of A2-73 is only referring to physiological conditions in which one wants the compound to be inactive. Whereas, A2-73 is effective, and more so than other SR1 antagonist mentioned, in pathological conditions, which is where you want to antagonise SR1 along with its Allosteric modulation of e.g. of M1.

The Missling Firetruck analogy that only leaves the fire station to do its work when there is a fire.

It would be rather odd for Tangui Maurice, who is an Anavex SAB member and proponent of A2-73, to write an entire paper concluding that A2-73 is the most ineffective compound.